TG Therapeutics Inc (TGTX) concluded trading on Thursday at a closing price of $34.55, with 5.84 million shares of worth about $201.66 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 103.47% during that period and on November 21, 2024 the price saw a gain of about 10.91%. Currently the company’s common shares owned by public are about 151.42M shares, out of which, 140.42M shares are available for trading.
Stock saw a price change of 12.01% in past 5 days and over the past one month there was a price change of 49.37%. Year-to-date (YTD), TGTX shares are showing a performance of 102.28% which increased to 180.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.25 but also hit the highest price of $36.50 during that period. The average intraday trading volume for TG Therapeutics Inc shares is 3.69 million. The stock is currently trading 21.83% above its 20-day simple moving average (SMA20), while that difference is up 36.10% for SMA50 and it goes to 76.15% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TG Therapeutics Inc (NASDAQ: TGTX) currently have 151.42M outstanding shares and institutions hold larger chunk of about 65.33% of that.
The stock has a current market capitalization of $5.38B and its 3Y-monthly beta is at 2.20. It has posted earnings per share of -$0.11 in the same period. It has Quick Ratio of 3.91 while making debt-to-equity ratio of 1.32. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TGTX, volatility over the week remained 7.86% while standing at 7.99% over the month.
Stock’s fiscal year EPS is expected to drop by -40.74% while it is estimated to increase by 1718.76% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on October 29, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by Goldman stated TG Therapeutics Inc (TGTX) stock as a Neutral in their note to investors on August 02, 2023, suggesting a price target of $12 for the stock. On June 26, 2023, Jefferies Resumed their recommendations, while on May 20, 2022, BofA Securities Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from B. Riley Securities on February 23, 2022.
